cisplatin + cyclophosphamide + doxorubicin + lomustine + vincristine

This drug is a combination chemotherapy regimen consisting of five cytotoxic agents used primarily in cancer treatment. Each component has a distinct mechanism of action targeting cancer cells: - Cisplatin is a platinum-based alkylating agent that forms DNA crosslinks, leading to apoptosis. - Cyclophosphamide is an alkylating agent that interferes with DNA replication and transcription. - Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, causing DNA damage. - Lomustine (CCNU) is a nitrosourea alkylating agent capable of crossing the blood-brain barrier, used especially in brain tumors. - Vincristine is a vinca alkaloid that inhibits microtubule formation, arresting cell division at metaphase. This multi-agent chemotherapy combination leverages different mechanisms to maximize antitumor efficacy across various malignancies such as advanced thymoma, ovarian cancer, gliomas, and other solid tumors. The regimen aims to improve response rates and survival outcomes by combining drugs with complementary actions.